E Ground Hog Day

Another snow day and lots of breaking news, mostly in the drug sector which I overweight. Moreover, it is Groundhog Day and the bad weather is likely to continue. I decided that I am more concerned about Alexei Navalny than Aung Sun Suu Kyi, despite her being of my sex and age, while he is a brave younger man. I will not discuss the collapse of the silver long moves and the future of GameStop, both chopped today. I am going to focus on stock news. I have access to my brokerage account again but there are still internet gaps.

Business newspaper article

image source


*Ikahest, Inc., a US sub of Grifols of Barcelona, published a peer-reviewed article in Alzheimer's and Dementia about the safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's after phase 2 trial yesterday. The 100 and 250-milliliter doses delivered by intervenous injection both worked.

Treated patients shows lower cognitive and functional decline during the 24-week study period. The trial is being run by the Barcelona parent along with Ikahest, a specialist in treatments for aging diseases, whose Chairman-CEO Karoly Nikolich explained what the learned journal had published. Patients got 5 doses in week 1; another 5 doses in week 13; and were followed up for 11 more weeks.

However, yesterday also saw not quoted on Q, my source because my brokerage account could not be accessed. Grifols A shares are listed in Spain and are included in the Mercado Continuo with ADRs on Q. GRFS is sometimes blocked because it has 2 stock classes in Spain, voting and non-voting, not new. It was founded in 1909. Yes, where it is legal it pays for plasma donations. Its main business is plasma for transfusion, but it researches benefits from plasma world-wide. Its B shares trade as GIFLY.

Thanks to the Wall Street drop of GRFS yesterday, which may be reversed, the share fell 74 cents to $17.37 while the market was focusing on short squeezes. Today it fell another 0.9% to $17.34. The Spanish firm operates in 100 countries and has several US arms. Its Alzheimer's research is being done by Ikahest, HQ'd near Los Angeles, which Grifols acquired from its owners, including Mr. Nikolich who founded it 40 years ago after leaving Genentech. The drug is a plasma fraction that cut neuroinflammation and learning and memory lapses in animal models and is now being tested in humans. I just bought some more GRFS at the market.

1 2 3 4
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
William K. 3 weeks ago Member's comment

Interesting news indeed, especially about that new vaccine. Will it have any effect on us in the USA? That part is unknown. Will others copy it? Probably.